… and skin rash in the ERL arm. Conclusions: MTA and ERL have a good toxicity profile and
demonstrated a comparable efficacy as salvage treatment in patients with advanced NSCLC. …

… PEM + ERL arm. A Japanese phase II trial of erlotinib monotherapy in pretreated patients
with advanced NSCLC with wild-type EGFR by Yoshioka (Okayama Lung Cancer Study Group …

… Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients
with advanced non-small cell lung cancer: a phase I dosefinding study. BMC Cancer 2012;…

… In a wide cohort of pretreated patients with NSCLC, the addition of sunitinib to erlotinib
significantly increased RR (10.6% versus 6.9%; p = 0.0471) and PFS (3.6 versus 2.0 months, HR …

… sorafenib and 150 mg daily erlotinib. Pharmacokinetic analysis revealed no significant effect
of erlotinib on the pharmacokinetic profile of sorafenib. Among 15 evaluable patients, 3 (20…

… Pretreatment and co-administration of TARCEVA decreased the AUC of CYP3A4 substrate,
midazolam, by 24% [7]. The concomitant administration of omeprazole or ranitidine resulted …

… gemcitabine plus daily erlotinib regimen in patients with advanced … Patients and Methods:
Twenty-seven patients with metastatic … to receive chemotherapy with gemcitabine and erlotinib. …

… The current study failed to meet its primary endpoint, because there was no difference in TTP
between pemetrexed and erlotinib when administered to pretreated patients with advanced/…

… erlotinib (ERL), was mediated by induction of oxidative stress in human head and neck cancer
(HNSCC) cells. ERL … were pretreated with NAC (a thiol antioxidant) before ERL treatment, …

… /m 2 on day 1 plus erlotinib 150 mg daily on days 2–14; erlotinib 150 mg daily; or pemetrexed
… , pairwise comparisons of pemetrexed–erlotinib versus erlotinib or pemetrexed were then …